Relais

JESSICA TOOPS

Staff EPS/7027

SUBMITTED: ATTN:

PHONE: PRINTED: 2003-05-23 12:01:45

REQUEST NO.:REG-10063022 FAX:

E-MAIL: SENT VIA: Manual

REG Regular Copy Journal

DELIVERY: E-mail: jt332u@nih.gov REPLY: Mail:

THIS IS NOT A BILL.

NOTICE: THIS MATERIAL MAY BE PROTECTED BY COPYRIGHT LAW

1

(NIH)

PM

78 NEW REQUESTS (InterLibrary Loan Dept nih)

REQUEST 74 of 78

05-22-03 05:31PM Terminal 800 JOURNAL

Article Author:

Jellis, C

Article Title:

Genomic organization of the gene coding for the

costimulatory human B-lymphcyte antigen B7-2 (CD86)

Published:

Appears in Journal: Immunogentics; Date published: 1995;

Volume: 42; Issue: 2; Pages: 85-9; 1:1995: 5

Cited in:

Other information

Needed by:

12-31-03 Home Library:nih

PTYPE:0,p,i,10

Requester:

TOOPS, Jessica

Telephone: Address:

301-594-7645 EPS

7027

Rockville MD 20892

National Cancer Institute

Requester ID:

.p198551 12 I.L.L. Requests awaiting arrival

NOTICE: THIS MATERIAL MAY BE PROTECTED BY COPYRIGHT LAW (TITLE 17, U.S. CODE)

o rerio, in 121–173,

f zebrafish

ammalian

raten. Teil er Verlag,

K. Expan. Cyprinid

Гісһу, Н., Acad Sci

organiza.

B genes.

of the β_2 -8: 1-10,

i, F., and the carp.

S., Gates, sen, J. S., M., and Science

method 06-425,

ing with /SA 74:

Klein, J. orphism, 1993 Klein, J. hydanio

J. Mhcimplica-Evol 8:

ORIGINAL PAPER

Cindy L. Jellis · Sophia S. Wang · Paul Rennert Frank Borriello · Arlene H. Sharpe · Nancy R. Green Gary S. Gray

Genomic organization of the gene coding for the costimulatory human B-lymphocyte antigen B7-2 (CD86)

Received: 8 December 1994 / Revised: 27 March 1995

Abstract The generation of an antigen-specific T-cell response requires that the T lymphocyte receive two signals from the antigen presenting cell. The specificity of this response is provided by antigen presented to lymphocyte and involves stimulation the T lymphocyte via the T-cell receptor (TCR)/CD3 complex. The second, or costimulatory signal, can be provided by ligation of the B-lymphocyte activation antigens B7-1 (CD80) and B7.2 (CD86) to TCR antigen CD28. The cDNAs for both CD80 and CD86 have been isolated and are predicted to encode type 1 membrane proteins of the immunoglobulin (Ig) superfamily. The predicted protein is composed of a signal peptide followed by two Ig-like extracellular domains, a transmembrane domain, and a cytoplasmic tail. Here we report that the genomic organization of CD86 reflects its functional structure, and is similar to that found for CD80. The gene is composed of eight exons which span more than 22 kilobases. The predicted protein functional domains of signal peptide, extracellular IgV- and IgC-like regions, and transmembrane domain coincide with the genomic structure. Two independent sequences had been reported for CD86 cDNA which differed in their 5'untranslated (UT) regions. We find CD86 exons 1 and 2 correspond to these alternate 5'UT sequences. Splicing of exon 1 or 2 with the signal peptide encoding exon 3 would produce mRNA transcripts complementary to the reported cDNA clones. Exons 4 and 5 correspond to IgV- and IgC-like extracellular domains, respectively. Exon 6 encodes the transmembrane region and beginning of the cytoplasmic tail. Exons 7 and 8 encode the remainder of the cytoplasmic tail and 3'UT sequences.

Introduction

The induction of an immune response requires that the responding T cells receive both a primary signal delivered through the T-cell receptor (TCR)/CD3 complex (June 1991; Klausner and Samelson 1991) and a second or costimulatory signal (Jenkins and Schwartz 1987; Umetsu et al. 1987; Nisbet-Brown et al. 1987). The B-lymphocyte activation antigens B7-1 [(CD80) (Gimmi et al. 1991; Koulova et al. 1991; Linsley et al. 1991a, b; Freeman et al. 1991; Reiser et al. 1992) and B7-2 (CD86) (Boussiotis et al. 1993; Azuma et al. 1993; Freeman et al. 1993; Engel et al. 1994)] can deliver a costimulatory signal via the T cell CD28 pathway. Inhibition of the B7/CD28 binding in the presence of TCR signaling leads to the development of antigen-specific anergy. (Gimmi et al. 1991). Blockage of the B7/CD28 pathway has led to the induction of antigenspecific tolerance and to engraftment of transplanted organs in a variety of animal models (Harding et al. 1992; Turka et al. 1992; Lenschow et al. 1992; Pescovitz et al. 1994; Blazar et al. 1994; Pearson et al. 1994).

The DNA sequence and predicted protein sequence of CD86 exhibits homology with CD80. Both proteins are composed of two extracellular domains related to the immunoglobulin (*Ig*) superfamily, a hydrophobic transmembrane region and a cytoplasmic domain. Despite their structural similarities and their ability to function as costimulatory molecules, CD80 and CD86 may have distinct roles. Both are expressed on activated B cells, activated monocytes, activated and resting dendritic cells, and activated T cells, and are absent from resting B and T cells (Freeman et al. 1993). CD86 alone appears on resting monocytes. While both CD80 and CD86 are expressed on

MA 02115, USA

The nucleotide sequence data reported in this paper have been submitted to the EMBL/GenBank nucleotide sequence databases and have been assigned the accession numbers U17715 (HSB72S1), U17716 (HSB72S2), U17717 (HSB72S3), U17718 (HSB72S4), U17719 (HSB72S5), U17720 (HSB72S6), U17721 (HSB72S7), and U17722 (HSB72S8)

C. L. Jellis (⋈) • S. S. Wang • P. Rennert • N. R. Green • G. S. Gray Repligen Corporation, One Kendall Square, Building 700, Cambridge, MA 02139, USA

F. Borriello · A. H. Sharpe Immunology Research Division, Departments of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston,

B cells after induction, the kinetics and level of expression vary according to the inductive agent (Lenschow et al. 1994). Similarly, IFN- γ treatment of dendritic cells induces increased expression of CD86 alone (Larsen et al. 1994). The appearance of the two costimulatory molecules on different cell types at different times suggests that they may play unique roles in modulating an immune response.

Two CD86 cDNA sequences have been reported (Azuma et al. 1993; Freeman et al. 1993). These sequences are identical in their coding regions but diverge in their 5'UT and 3'UT sequences. In this study, we report the genomic structure of the human CD86 gene and show that both of the different reported 5'UT sequences exist as exons adjacent to the coding region.

Materials and methods

Screening the human genomic P1 library for CD86

The DuPont Merck Pharmaceutical Company Human Foreskin Fibroblast P1 Library #1 (DMPC-HFF#1) was screened for *CD86* by Genome Systems (St. Louis, MO) using PCR primers complementary to *CD86* cDNA (Freeman et al. 1993). The four DNA primers used for polymerase chain reaction (PCR) screening of this library were as follows:

"J5", 5'-CACGGTTACCCAGAACCTAAG-3'; "J6", 5'GGTGAAGA-TAAAAGCCGCGTC-3'; "J7", 5'-CACAGGGTGAAAGCTTTGC-3';

and "J8", 5'-GGGATCCATTTTGGCTGC-3'.

PCR primers J5 and J6 are sense and antisense primers derived form the IgC-like domain of *CD86* and generate a 212 base pairs (bp) PCR product. PCR primers J7 and J8 are sense and antisense primers derived from the 5'UT *CD86* sequence published by Freeman and coworkers (1993) and generate a 115 bp PCR product. PCR conditions used to identify *CD86*-specific P1 clones consisted of 30 cycles each composed of denaturation at 94 °C for 30 s, annealing at 55 °C for 1 min, and extension at 72 °C for 1 min.

Preparation of DNA from CD86 genomic P1 clones for direct sequencing

P1 DNA was transferred into Escherichia coli (E. coli) host DH10B to allow preparation of DNA suitable for direct double-strand cycle sequencing. This was accomplished by two rounds of Hfr-mediated mating utilizing E. coli strains NS3529 and DH10B and protocols provided by Genome Systems. DH10B cells containing DMPC-HFF#1 P1 clone 1390-A1 or clone 1307-7C DNA were selected based on their acquired resistance to chloramphenicol (encoded by the F' episome) and kanamycin (encoded on the P1 plasmid). Plasmid DNA suitable for direct sequencing was prepared from a 500 ml yeast tryptone broth culture containing kanamycin (25 ug/ml) that had been inoculated with 5 ml of an overnight culture. The cultures were incubated at 37 °C at 250 RPM for 30 min, IPTG was added to a final concentration of 1 mM to induce the P1 lytic operon and cells were harvested 5 h post induction. The cells were collected by centrifugation and P1 plasmid DNA prepared by the triton lysis method (protocol provided by Genome Systems). Final yield of P1 DNA was approximately 25 ug/ 500 ml culture.

Sequencing CD86 P1 clones

Oligonucleotide primers complementary to CD86 cDNA were used to sequence exon/intron boundaries in both directions. Cycle sequencing was carried out with an ABI (Foster City, CA) prism kit using 1 ug of P1 template DNA, 4.8 pmol primer, and 30 cycles each consisting of

denaturation at 97 °C for 15 s, followed by annealing at 55 °C for 15 s, and extension at 60 °C for 4 min. Reactions were purified on "Bakerbond spe" (J. T. Baker, Phillipsburg, NJ) 1-ml disposable filtration columns and the DNA was precipitated with the addition of 2.5 volumes of ethanol. Precipitated DNA was resuspended in 5 ul of a 4:1 mixture of formamide: 50 mM ethylenediaminetetraacetate, heated for two min at 95 °C, placed on ice, and the sequence determined using an ABI 373A automated sequencer (ABI).

Southern blot analysis of restriction enzyme-digested P1 DNA

For Southern blot analysis (Southern 1975), DNA was prepared from 500 ml IPTG-induced cultures of CD86 genomic P1 clones #1390-A1/ DH10B and #1307-7C/DH10B using QIAGEN (Chatsworth, CA) protocols and reagents. Approximately 1 ug of plasmid DNA per reaction was digested with a panel of restriction endonucleases, and the digested DNA analyzed by agarose gel electrophoresis. The DNA was visualized by staining with ethidium bromide and transferred to nitrocellulose membrane filters. Oligonucleotides corresponding to CD86 exons and flanking intron sequences were synthesized and 3' end-labeled with fluorescein-dUTP (ECL 3' oligolabeling and detection system; Amersham, Arlington Heights, IL). Southern blots of restriction enzyme-digested DNA prepared from both clones were probed with fluorescein dUTP-labeled oligonucleotides. The hybridized oligonucleotides were detecting using anti-fluorescein HRP conjugate antibodies (Amersham). The sizes of the restriction fragments were estimated by comparison with ECL DNA markers (Amersham) designed for use with this system.

Confirmation of intron sizes by PCR

The length of introns determined by Southern blot analysis were confirmed by PCR analysis using primers complementary to exon sequences at the exon intron boundaries and directed towards adjacent exons. Template DNA (20 ng) and 100 pmol of each sense and antisense primer were mixed and denatured at 97 °C for 2 min. The intron sequences were PCR amplified using 30 cycles each composed of a denaturation at 95 °C for 1 min, annealing at 55 °C for 1 min, and extension at 72 °C for 4 min. PCR products were analyzed on agarose gels, transferred to nitrocellulose, and probed with a variety of labeled intron and exon primers to measure size and to confirm integrity.

Results

Two human genomic P1 clones were identified by probing with CD86-specific PCR primers provided by Genome Systems. P1 human genomic clone 1390-A1 was positive in PCR reactions with primers J7 and J8, specific for CD86 5'UT sequences, and negative in PCR reactions using the IgC-like domain primers J5 and J6. P1 human genomic clone 1307-7C gave the expected 212 bp PCR product with IgC-like domain primers J5 and J6 and was negative in PCR reactions, using the 5'UT primers J7 and J8. Southern blots of restriction enzyme-digested clone 1390-A1 and clone 1307-7C P1 DNA were probed with exon-specificlabeled oligonucleotides to assign CD86 exons to their respective genomic clones. Both reported 5'UT exon sequences were localized to P1 clone 1390-A1. The signal peptide, Ig-like extracellular, transmembrane, and cytoplasmic domains were localized to P1 clone 1307-7C.

DNA sequencing of intron/exon boundaries was performed directly on P1 CD86 genomic DNA using primers derived from CD86 cDNA sequences. All junctions were

-2 (CD86)

C for 15 s, on "Bakerfiltration 5 volumes 1 mixture r two min using an

lA

ared from 1390-A1/ orth, CA) DNA per ases, and The DNA sferred to onding to ad and 3' nd detecblots of nes were the hybriein HRP

ion frag-


(Amers-


sis were to exon adjacent ense and nin. The omposed min, and agarose f labeled crity.

orobing enome ositive · CD86 ng the enomic ct with tive in outhern .1 and ecificon sesignal

s perrimers were

oplas-





2 Kb

Fig. 1 Exon-intron organization of the human CD86 gene. The CD86 gene contains eight exons shown as solid boxes. Exons 1 and 2 are alternately spliced to exon 3 to yield different CD86 mRNA transcripts. P1 clones containing CD86 genomic sequences are shown below, along with recognition sites for Hin dIII (H), Not 1 (N), and Sfi (S) restriction endonucleases. The broken line indicates genomic sequences present in P1 clones which extend for an additional 60-70 kb as estimated from the packaging requirements for bacteriophage P1 (Sternberg 1990) and measured here

found to have conventional splice signal sequences (Shapiro and Senapathy 1987) and the CD86 coding sequences were found dispersed over eight exons. Exons 1 and 2 encode the 5'UT sequences reported by Freeman and coworkers (1993) and by Azuma and co-workers (1993), respectively. Exon 3 encodes the predicted signal peptide and exons 4 and 5 encode the two Ig-like extracellular domains. Exon 6 encodes the transmembrane and part of the cytoplasmic domain. Exons 7 and 8 encode a portion of the cytoplasmic domain and the remainder of the cytoplasmic and 3'UT domains, respectively.

Introns were sized by Southern blot analysis of restriction enzyme-digested DNA and by PCR using primers directed across the introns from bordering exons. The results show that the CD86 gene spans at least 23 kilobases (kb) (Fig. 1)]. The length of the introns determined ranged in size from 1.2 kb to 5.5 kb as shown in Figure 2. The length of intron B separating exons 2 and 3 was greater than 4.3 kb. The exact length was not determined because CD86 genomic clones 1390-A1 and 1307-7C do not overlap. This was confirmed by probing Southern blots of clone 1390-A1 restriction enzyme-digested DNA with a fluorescein dUTPlabeled oligonucleotide corresponding to the N-terminal sequences of CD86 genomic clone 1307-7C. The N-terminal sequences of clone 1307-7C were determined by direct sequencing using T7 primer sequences located in the vector adjacent to the cloned genomic DNA. These T7 primer sequences are adjacent to the Not 1 restriction site at the N-terminus of 1307-7C shown in Figure 1. The nucleotide sequences of the CD86 exons along with several hundred bases of bordering intron sequences are shown in Figure 2.

Discussion

The two independent cDNA sequences reported for the CD86 gene contained identical coding sequences for the CD86 protein region but had different 5'UT sequences. The existence of both of the 5'UT sequences was confirmed by DNA sequencing of the CD86 genomic DNA. In the CD86 gene, exons 1 and 2 correspond to these alternate 5'UT regions. The isolation of the two CD86 cDNAs suggests that the expression of this gene may be regulated at the transcriptional or RNA splicing level, which could give rise to tissue-specific expression of CD86. The CD86 cDNA isolated by Freeman and co-workers (1993) was found in a library prepared from activated human B lymphocytes, while that reported by Azuma and co-workers (1993) was found in a library prepared from the JY B-lymphoblastoid (B-LBL) cell line. The alternate 5'UT regions found in the two cDNAs may reflect this difference in the source of cell for the preparation of the respective libraries. The JY B-LBL cell line constitutively expressed CD86 at high levels and was the source of the CD86 cDNA which started with exon 2. Activated human B lymphocytes were the source of the cDNA starting with the exon 1 sequence. The two CD86 cDNA with alternate 5'UT sequences may represent constitutively expressed and inducible forms of CD86. We found the divergence of these CD86 cDNA sequences to occur precisely at exon 3 (Fig. 2), which encodes the predicted secretory signal peptide. An exon 1/3 splice event gives rise to the cDNA clone isolated from activated human B lymphocytes as described by Freeman and co-workers (1993). Alternatively, splicing of exon 2 to exon 3 produces the CD86 cDNA clone isolated from the B-LBL cell line reported by Azuma and co-workers (1993). In both cDNAs, translation of the signal peptide probably initiates at the methionine codon in exon 3. The organization of the CD86 genome reflects the structural aspects of the CD86 protein. The signal peptide sequence, the two Ig family member Ig-like extracellular domains, and the transmembrane domain are located on individual exons. The cytoplasmic domain of CD86 is split between three exons (exons 6, 7, and 8) suggesting the possibility that alternate splicing could give rise to CD86 with different intracellular sequences. While alternate splicing of the cytoplasmic domain of CD86 has not been reported, multiple cytoplasmic domains do exist for the mouse homologue of CD80 (Borriello et al. 1994).

The genomic organization of CD86 is similar to that reported for CD80. The 5'UT sequences were found on a separate exon. In CD86, exon 3 encodes a signal peptide, exon 4 contains the predicted IgV-like domain, exon 5 contains an Ig C-like domain, and exon 6 encodes a stretch of hydrophobic residues corresponding to the transmembrane domain. These regions correspond to exons 2 through 5 in CD80, respectively (Selvakumar et al. 1992). The genomic organization of CD80 and CD86 diverges at the 3' end of the gene. Notably, the cytoplasmic tail for CD86 spans three exons (exons 6 through 8) in contrast to being entirely contained in the final exon for CD80. No evidence

Exon 1

actgaattatatattuthtaatacatatayacctacgtcaatgagtttaaactgcaaggaaagggttaaatttottoc tcaagtytggtcaaaatchgtayagaaaagaggaacagcttotottaaagaaagttagctygggtaggtatacagacat toccgaogaaggcttg

CACAGGGTGAAAGCTTTGCTTCTCTGCTGCTGTAACAGGGACTAGCACAGACACAGGATGAGTGGGGTCATTTCCAGATTAGGTCACAGGAGAAGCAGCCAAAATGGATCCCCAGTG

 $\label{thm:constraint} gtgagtaataattettattetttgeagagaagttatgagttgtgactgeagggaaaggetgaaggttgaagatggtgetttgatgtgtgtettettetacaaaaggetgatgagaagatgttetttttetacaaaaggetetttggeacataaaaggeagagaattatttgeaatgeeeaaageagtteat.....Intron. <math>\lambda$ (3.0 Kb).....

Exon 2

 $\dots to cot type to the test of the test of$

AGGASCCTTAGGASGTSCGGGGAGCTCGCGATACTCCTTTTGGTTTATCTTACCACCTTGCTTCTGTGTTCCTTGGGATACCTCCTTTTTGGACCACCACTGGCACTTTGTGACAG

gtatgtttgtggaggeteagaegeetagggagtgesatgagataaagetgesagetgestetettggggeagaaatgetga tgtgetaatggeeggeeagagaataagtaaaagggattgesagagaatgettaaaaeetetgseeateeaggtttge tteteagattgaetaeattggaggtgggatattaeaaaaatetgtetetteetgeeagateeetteatetgtte... . Intron 8 (24.3 Mp).....

Exon 3

.....agaaacatottttotgocoacaattocattggotagaaaccagtotcatggoctgtataactgoaggggaggo tgggaaatgtgacotatogatggagotaagagoaaaasggaattggotttgatgaagoootggoattgtototgoacac cogagaacccaagtgaatoocaaactocacgtocaagtoatgtittlggtgaacateggttitcagtittootttiotaa toaagtittacotttittitotogactotag

CACT ATG GGA CTG AGT AAC ATT CTC TTT GTG ATG GGC TTC CTG CTC TCT G Met Gly Leu Ser Asn lle Leu Phe Val Met Ala Phe Leu Leu Ser G

gtaagaacotttoagotttgttaagtootggaatootaotgtotootgatgagtotgaocaoaggaagooaggootga gaottggggggttttaotoaotttotaotgagoattggaoaagaocaoatgcaaaaaagaotttootggagaagaagg aagtgttatgattgagag....<u>Intron C (1.2 Kb)</u>.....

Evon A

- 10 m

ş

7 (000000)

....aactgaggotoatgaagagttgoaggttgtacoaggooocacatttagtoagoggtgaagocaggaccaaggt cotaatotocagatgoccagcagatgtgcacagttocagaacttaatatottattottoagoatgattactggataaga tagtatotgggttattgtataaagagaaatggaggttttttococultoctottgtttotocotocotaatoottaacttaac ttottttttag

(+1) GT GCT GCT CCT CTG GAG ATT CAA GCT TAT TTC AAT GAG ACT GCA GAC CTG CCA TGC CAA ly Ala Ala Pro Leu Glu Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro Cys Gln

TTT GCA AAC TCT CAA AAC CAA AGC CTG AGT GAG CTA GTA GTA TTT TGG CAG GAC CAG Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Asp Leu Val Val Phe Trp Gln Asp Gln

GAA AAC TTG GTT CTG AAT GAG GTA TAC TTA GGC AAA GAG AAA TTT GAC AGT GTT CAT Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly Lys Glu Lys Phe Asp Ser Val His TCC AAG TAT ATG GGC CGC ACA AGT TTT GAT TCG GAC AGT TGG ACC CTG AGA CTT CAC Ser Lys Tyr Met Gly Arg Thr Ser Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His

AAT CTT CAG ATC AAG GAC AAG GGC TTG TAT CAA TGT ATC ATC CAT CAC AAA AAG CCC Asn Leu Gln Ile Lys Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro

ACA GGA ATG ATT CGC ATC CAC CAG ATG AAT TOT GAA CTG TCA GTG CTT G Thr Gly Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu A

for alternate splicing of *CD86* cytoplasmic exons is found in the two published *CD86* cDNA sequences, however, they do differ in the extent of their 3'UT sequences. This difference may be due to the existence of two polyadenylation signals in exon 8. An alternate polyadenylation signal was also noted for *CD80* (Selvakumar et al. 1992).

In summary, the genomic organization of *CD86* coincides with structural protein components of signal peptide, extracellular, transmembrane, and cytoplasmic domains, but also reflects the potential for regulating the expression and signalling capacity of *CD86* through alternate splicing.

Exon

CT AAC TTC AGT CAA CCT GAA ATA GTA CCA ATT TCT AAT ATA ACA GAA AAT GTG TAC ATA la Aon Phe Ser Gin Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Aon Val Tyr Ile

AAT TTG ACC TGC TCA TCT ATA CAC GGT TAC CCA GAA CCT AAG AAG ATG AGT GTT TTG Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Fro Glu Pro Lys Lys Met Ser Val Leu

CTA AGA ACC AAG AAT TCA ACT ATC GAG TAT GAT GGT ATT ATG CAG AAA TCT CAA GAT Leu Arg Thr Lya Asn Ser Thr Ile Glu Tyr Asp Gly Ile Met Gln Lys Ser Gln Asp

AAT STO ACA GAA CTG TAC GAC STT TOO ATC AGC TTG TCT GTT TCA TTC CCT GAT GTT Asn Val Thr Glu Leu Ttp Asp Val Ser Ile Ser Leu Ser Val Ser Pho Pro Asp Val

ACG AGC AAT ATG ACC ATC TTC TGT ATT CTG GAA ACT GAC AAG ACG CGG CTT TTA TCT Thr Ser Asn Met Thr lie Phe Cys Asn Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser

TCA CCT TTC TCT ATA G Ser Pro Phe Ser Ile G

Exon 6

AG CTT GAG GAC CCT CAG CCT CCC CCA GAC CAC ATT CCT TGG ATT ACA GCT GTA CTT CCA lu Leu Glu Asp Pro Sin Pro Pro Pro Asp His Ile Rno Trp Ile The Ala Yal Leu Rno

ACA GTT ATT ATA TGT GTG ATG GTT TTC TGT CTA ATT CTA TGG AAA TGG AAG AAG Thr Val lie ile Cys Val Mei Val Phe Cys Leu lie Leu Txp Lys Trp Lys Lys Lys

AAG CGG CCT CGC AAC TCT TAT AAA TGT G Lys Arg Pro Arg Asn Ser Tyr Lys Cys G

Exon 7

....ttttggttagccaggatagagatataagtgggagatctatttccagtgttagaatttaaggcacagtgagaaz gggaaggcatatactttttgaatgcaagaaacttcttcccaatcccctgaaattgcatcatttgagtaactatctt tccatatataaagtcacaacaatttctctctcagtcccagaactttgaagccttttcaaactttccttctttggtat ctaggaggaatagatttttgaagattgttcttggtgtctttcag

GA ACC AAC ACA ATG GAG AGG GAA GAG AGT GAA CAG ACC AAG AAA AG ly Thr Asn Thr Met Glu Arg Glu Slu Ser Glu Gln Thr Lys Lys Ar

Exon 8

A GAA AAA ATC CAT ATA CCT GAA AGA TCT GAT GAA GCC CAG CGT GTT TTT AAA AGT ICG g Glu Lys Ile His Ile Pro Glu Arg Ser Asp Glu Ala Gln Arg Val Phe Lys Ser Ser

ANG ACA TOT TOA TOC GAC AAA AGT GAT ACA TGT TTO TAA TRAABGAGTAAAAGCCCATACAAGTA Lys Thr Ser Ser Cys Asp Lys Ser Asp Thr Cys Phe *

Fig. 2 Nucleotide sequence of the CD86 gene. Exon sequences, including 5' and 3'UT regions of CD86 mRNA, are shown in uppercase letters, with the translated amino acids below for protein-encoding regions. Lowercase type is used for intron sequences A through G. The first amino acid of the mature CD86 protein is indicated as +1. An asterisk denotes the stop codon. Alternate splicing of exon 1 or 2 to exon 3 yields CD86 mRNA transcripts with different 5'UT sequences. The hydrophobic residues which form the transmembrane domain are underlined with a dashed line in exon 6. Two potential polyadenylation signals are underlined with a solid line in exon 8

-2 (CD86)

seccagateaa setgettteag

STG TAC ATA Val Tyr Ile

GTT TTG Val Leu

CAA GAT Gln Asp

Asp Val

TTA TOT Leu Ser

:aatgtocceg :tgottotcot :actgactcag :Kbl

tagagecets etgattgaaa

MA CTT CCA

AAG AAG Lys Lys

. .

ooggagetty ageotatada acaatgtadt

acagtgagaaa taactatotot tottttggtat

ottatgootaa Eggaagaaaat Eoaagtaaaag ootggoacagt

iggttettte Attetgeesta Seag

NA AGT TCG /s Ser Ser

CATACAAGTA

VAGACATTACO COTATGACAA VATGGCTCATG

equences, in upperencoding th G. The s +1. An 1 or 2 to equences, omain are enylation

References

- Azuma, M., Ito, D., Yagita, H., Okumura, K., Phillips, J. H., Lanler, L. L., and Somoza, C. B70 antigen is a second ligand for CTLA-4 and CD28. *Nature 366*: 76–79, 1993
- Biazer, B. R., Taylor, P. A., Linsley, P. S., and Vallera, D. A. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. *Blood* 83: 3815–3825, 1994
- Borriello, F., Freeman, G. J., Edelhoff, S., Disteche, C. M., Nadler, L. M., and Sharpe, A. H. Characterization of the murine B7-1 genomic locus reveals an additional exon encoding an alternative cytoplasmic domain and a chromosomal location of chromosome 16, band B5. *J Immunol* 153: 5038-5048, 1994
- Boussiotis, V. A., Freeman, G. J., Gribben, J. G., Daley, J., Gray, G., and Nadler, L. M. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. *Proc Natl Acad Sci USA 90*: 11059-11063, 1993
- Engel, P., Gribben, J. G., Freeman, G. J., Zhou, L. J., Nozawa, Y., Abe, M., Nadler, L. M., Wakasa, H., and Tedder, T. F. The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. *Blood* 84: 1402-1407, 1994
- Freeman, G. J., Gray, G. S., Gimmi, C. D., Lombar, D. B., Zhou, L. J., White, M., Fingeroth, J. D., Gribben, J. G., and Nadler, L. M. Structure, expression, and T-cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med 174: 625-631, 1991
- Freeman, G. J., Gribben, J. G. Boussiotis, V. A., Restivo Jr, V. A.,
 Lombard, L. A., Gray, G. S., and Nadler, L. M. Cloning of B7-2:
 a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262: 909-911, 1993
- Gimmi, C. D., Freeman, G. J., Gribben, J. G., Sugita, K., Freedman, A. S., Morimoto, C., and Nadler, L. M. B cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete IL-2. Proc Natl Acad Sci USA 88: 6575-6579, 1991
- Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H., and Allison, J. P. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. *Nature* 356: 607-609, 1992
- Jenkins, M. J. and Schwartz, R. H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 165: 302-319, 1987
- June, C. H. Signal transduction in T cells. Curr Opin Immunol 3: 287-293, 1991
- Klausner, R. D. and Samelson, L. E. T cell antigen receptor activation pathways: the tyrosine kinase connection. *Cell* 64: 875-878, 1991
- Koulova, L., Clark, E. A., Shu, G., and Dupont, B. The CD28 ligand B7/BB1 provides a costimulatory signal for alloactivation of CD4+T cells. *J Exp Med 173*: 759–762, 1991
- Larsen, C. P., Ritchie, S. C., Hendrix, R., Linsley, P. S., Hathcock, K. S., Hodes, R. J., Lowry, R. P., and Pearson, T. C. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. *J Immunol* 152: 5208-5219, 1994

- Lenschow, D. J., Zeng, Y., Thistlewaite, J. R., Montag, A., Brady, W., Gibson, M. G., Linsley, P. S., and Bluestone, J. A. Long term survival of xenogeneic pancreatic islets induced by CTLA4Ig. Science 257: 789-792, 1992
- Lenschow, D. J., Sperling, A. I., Cooke, M. P., Freeman, G., Rhee, L., Decker, D. C., Gray, G., Nadler, L. M., Goodnow, C. C., and Bluestone, J. A. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J Immunol 153: 1990-1997, 1994
- Linsley, P. S., Brady, W., Grosmaire, L. S., Aruffo, A., Damle, N. K., and Ledbetter, J. A. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and IL-2 mRNA accumulation. *J Exp Med* 173: 721-730, 1991 a
- Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., and Ledbetter, J. A. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174: 561-569, 1991 b
- Nisbet-Brown, E. R., Lee, J. W., Cheung, R. K., and Gelfand, E. W. Antigen-specific and non specific mitogenic signals in the activation of human T cell clones. *J Immunol* 138: 3713-3719, 1987
- Pearson, T. C., Alexander, D. Z., Winn, K. J., Linsley, P. S., Lowry, R. P., and Larsen, C. P. Transplantation tolerance induced by CTLA4Ig. *Transplantation* 57: 1701-1706, 1994
- Pescovitz, M. D., Yang, R., Liu, Q., Collins, M. H., and Grosfeld, J. L. CD28-pathway blockade with CTLA4Ig leads to prolongation of small bowel transplant survival in rats. *Transplant Proc* 26: 1618-1619, 1994
- Reiser, H., Freeman, G. J., Razi-Wolf, Z., Gimmi, C. D., Benacerrof, B., and Nadler, L. M. Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. *Proc Natl Acad Sci USA* 89: 271-275, 1992
- Selvakumar, A., Mohanraj, B. K., Eddy, R. L., Shows, T. B., White, P. C., and Dupont, B. Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7. *Immunogenetics* 36: 175–181, 1992
- Shapiro, M. B. and Senapathy, P. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. *Nucleic Acids Res* 15: 7155-7174, 1987
- Southern, E. M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 98: 503-517, 1975
- Sternberg, Nat. L. A bacteriophage P1 cloning system for the isolation, amplification and recovery of DNA fragments as large as 100 kb. Proc Natl Acad Sci USA 83: 103-107, 1990
- Turka, L. A., Linsley, P. S., Lin, H., Brady, W., Leiden, J. M., Wei, R. Q.,
 Gibson, M. L., Zheng, X. G., Myrdal, S., Gordon, D., Bailey, T.,
 Bolling, S. T., and Thompson, C. B. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. *Proc Natl Acad Sci USA 89*: 11102-11105, 1992
- Umetsu, D. T., Katzen, D., Chatila, T., Miller, R., Jabara, H. H., Maher, M., Oettgen, H., Terhost, C., and Geha, R. S. Requirements for activation of human peripheral blood T cells by mouse monoclonal antibody to CD3. Clin Immunol Immunopathol 43: 48-64, 1987